VolitionRx Files Patent for Nu.Q Ebola Triage Test

VolitionRx Limited (NYSE American: VNRX) has announced a strategic patent application for using its proprietary Nu.Q technology to triage and monitor patients suspected of Ebola virus infection. This application extends the company's existing Nu.Q(R) NETs test, which measures circulating nucleosomes and neutrophil extracellular traps—early indicators of hyper-inflammation linked to septic shock and mortality. Volition's CE-Marked automated Nu.Q NETs assay, along with a newly developed finger-prick lateral flow detection prototype, could offer a low-cost bedside triage solution during Ebola outbreaks, especially in resource-constrained regions. The company is actively seeking partnerships with global health organizations, pharmaceutical developers, NGOs, and distribution partners to support field trials, manufacturing scale-up, and potential deployment in outbreak zones.

Volition is a multinational company focused on advancing epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring. Through its subsidiaries, Volition develops and commercializes simple, cost-effective blood tests for detecting and monitoring diseases like cancers and sepsis. The company's research and development activities are centered in Belgium, with an innovation lab in the U.S. and an office in London. This move into Ebola diagnostics highlights Volition's commitment to addressing critical global health challenges.

For the full press release, visit https://ibn.fm/UOWP1. The announcement was disseminated by BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides services such as press release enhancement, social media distribution, and editorial syndication to over 5,000 outlets. BioMedWire focuses on the latest developments in Biotech, BioMed, and Life Sciences sectors.